Treatment of dry age-related macular degeneration

Marco A. Zarbin, Philip J Rosenfeld

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

We have entered the era of pathwaybased therapy for the early and late manifestations of AMD. Each of the treatments mentioned in this chapter acts at a putative step in the pathogenesis of AMD. Steps that have been targeted thus far include oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. β -amyloid accumulation), and apoptosis. In principle, these therapies can be combined ('combination therapy'), which may lead to synergistic effects that include better visual outcome, less likelihood for 'escape' (i.e. drug resistance), and less frequent treatment.

Original languageEnglish (US)
Title of host publicationMedical Retina
PublisherS. Karger AG
Pages134-142
Number of pages9
Volume1
ISBN (Print)9783805599917, 9783805599900
DOIs
StatePublished - May 24 2012
Externally publishedYes

Fingerprint

Lipofuscin
Macular Degeneration
Amyloid
Chemical activation
Apoptosis
Pharmaceutical Preparations
Complement Activation
Drug Resistance
Extracellular Matrix
Therapeutics
Inflammation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Zarbin, M. A., & Rosenfeld, P. J. (2012). Treatment of dry age-related macular degeneration. In Medical Retina (Vol. 1, pp. 134-142). S. Karger AG. https://doi.org/10.1159/000336761

Treatment of dry age-related macular degeneration. / Zarbin, Marco A.; Rosenfeld, Philip J.

Medical Retina. Vol. 1 S. Karger AG, 2012. p. 134-142.

Research output: Chapter in Book/Report/Conference proceedingChapter

Zarbin, MA & Rosenfeld, PJ 2012, Treatment of dry age-related macular degeneration. in Medical Retina. vol. 1, S. Karger AG, pp. 134-142. https://doi.org/10.1159/000336761
Zarbin MA, Rosenfeld PJ. Treatment of dry age-related macular degeneration. In Medical Retina. Vol. 1. S. Karger AG. 2012. p. 134-142 https://doi.org/10.1159/000336761
Zarbin, Marco A. ; Rosenfeld, Philip J. / Treatment of dry age-related macular degeneration. Medical Retina. Vol. 1 S. Karger AG, 2012. pp. 134-142
@inbook{d0ec2d504d3945e6ab1ae3e3fba7f2cc,
title = "Treatment of dry age-related macular degeneration",
abstract = "We have entered the era of pathwaybased therapy for the early and late manifestations of AMD. Each of the treatments mentioned in this chapter acts at a putative step in the pathogenesis of AMD. Steps that have been targeted thus far include oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. β -amyloid accumulation), and apoptosis. In principle, these therapies can be combined ('combination therapy'), which may lead to synergistic effects that include better visual outcome, less likelihood for 'escape' (i.e. drug resistance), and less frequent treatment.",
author = "Zarbin, {Marco A.} and Rosenfeld, {Philip J}",
year = "2012",
month = "5",
day = "24",
doi = "10.1159/000336761",
language = "English (US)",
isbn = "9783805599917",
volume = "1",
pages = "134--142",
booktitle = "Medical Retina",
publisher = "S. Karger AG",

}

TY - CHAP

T1 - Treatment of dry age-related macular degeneration

AU - Zarbin, Marco A.

AU - Rosenfeld, Philip J

PY - 2012/5/24

Y1 - 2012/5/24

N2 - We have entered the era of pathwaybased therapy for the early and late manifestations of AMD. Each of the treatments mentioned in this chapter acts at a putative step in the pathogenesis of AMD. Steps that have been targeted thus far include oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. β -amyloid accumulation), and apoptosis. In principle, these therapies can be combined ('combination therapy'), which may lead to synergistic effects that include better visual outcome, less likelihood for 'escape' (i.e. drug resistance), and less frequent treatment.

AB - We have entered the era of pathwaybased therapy for the early and late manifestations of AMD. Each of the treatments mentioned in this chapter acts at a putative step in the pathogenesis of AMD. Steps that have been targeted thus far include oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. β -amyloid accumulation), and apoptosis. In principle, these therapies can be combined ('combination therapy'), which may lead to synergistic effects that include better visual outcome, less likelihood for 'escape' (i.e. drug resistance), and less frequent treatment.

UR - http://www.scopus.com/inward/record.url?scp=84958600506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958600506&partnerID=8YFLogxK

U2 - 10.1159/000336761

DO - 10.1159/000336761

M3 - Chapter

SN - 9783805599917

SN - 9783805599900

VL - 1

SP - 134

EP - 142

BT - Medical Retina

PB - S. Karger AG

ER -